Core Viewpoint - The establishment of a new wholly-owned subsidiary, Shenzhen Kehua Weijian Technology Co., Ltd., by Kehua Bio (002022.SZ) aims to align with the company's strategic development, focusing on the in vitro diagnostics industry while exploring potential collaborations in artificial intelligence and robotics [2]. Group 1 - Kehua Bio announced the establishment of Shenzhen Kehua Weijian Technology Co., Ltd. on August 5, 2025, to support its development strategy [2]. - The company has been deeply involved in the in vitro diagnostics industry for many years and has not yet engaged in artificial intelligence or robotics research and development [2]. - Kehua Bio is enhancing its external technical cooperation by collaborating with universities, research institutions, and innovation centers to create an open innovation platform [2].

（文章来源：证券日报） 证券日报网讯科华生物8月13日在互动平台回答投资者提问时表示，公司目前未开展机器人业务。 ...

证券日报网讯科华生物8月13日在互动平台回答投资者提问时表示，公司深耕体外诊断行业多年，目前 未开展机器人研发。 （文章来源：证券日报） ...

证券日报网讯科华生物（002022）8月13日在互动平台回答投资者提问时表示，公司重视市值管理的工 作。在资本市场中，股价受多种因素影响，除了公司内在价值的主因外，可能还会受到宏观经济形势、 行业趋势及投资者偏好等多重因素影响。对于公司而言，持续高质量发展是市值管理的基础，公司将持 续聚焦主营业务，采取多举措努力提升经营效率并积极发展业务，不断提升自身的综合实力，努力提升 公司内在价值。若公司存在股份变动涉及的披露事项，公司将严格按照法律法规的规定及时履行信息披 露义务。 ...

Core Viewpoint - The company has not yet developed a robotics business, but its colloidal gold products, specifically the anti-HIV test kits, have been recognized by the WHO procurement list, indicating strong customer validation of its products [1] Company Developments - The company's subsidiary, Xi'an Tianlong, has a chikungunya virus RNA test kit (fluorescent PCR method) that has not yet applied for the National Medical Products Administration's medical device registration, and it is currently only available as a research reagent for customs and disease control applications [1] - The sales proportion of the chikungunya virus test kit is small and has not significantly impacted the company's consolidated revenue [1]

Core Viewpoint - The stock price of Kehua Bio is reported at 7.58 yuan, reflecting a decrease of 0.27 yuan from the previous trading day, with a trading range of 5.48% and a transaction amount of 319 million yuan [1] Company Overview - Kehua Bio's main business includes the research and production of in vitro diagnostic reagents and medical testing instruments, with product lines covering immunodiagnostics, biochemical diagnostics, and molecular diagnostics, primarily used in medical institution laboratory testing [1] Regulatory Update - The company has recently obtained a medical device registration certificate for the C-reactive protein testing kit from the Shanghai Municipal Medical Products Administration, valid until August 6, 2030 [1] Financial Metrics - The latest data indicates that the company's total market capitalization is 3.899 billion yuan, with a price-to-earnings ratio of -18.30 times [1] Capital Flow - On the trading day, the net outflow of main funds for the stock was 18.32 million yuan, while the cumulative net inflow over the past five trading days was 15.94 million yuan [1]

Core Viewpoint - Shanghai Kehua Bio-engineering Co., Ltd. has received a medical device registration certificate for in vitro diagnostic reagents, which is expected to positively impact the company's business development [1]. Group 1 - The company has obtained a medical device registration certificate from the Shanghai Municipal Drug Administration [1]. - The new product registration enriches the company's product line [1]. - The company is currently unable to predict the future revenue impact of the new products [1].

产品系C-反应蛋白（CRP）测定试剂盒（胶乳免疫比浊法），供医疗机构用于体外定量测定人血清和血 浆样本中的C-反应蛋白（CRP）含量，临床上用于非特异性炎症的辅助诊断。新产品医疗器械注册证的 取得，丰富了公司产品线，将对公司业务发展具有正面影响。 （企业公告） 8月11日，科华生物发布关于产品获得医疗器械注册证的公告。披露公司收到上海市药品监督管理局颁 发的医疗器械注册证（体外诊断试剂）。 ...

Core Insights - The company Kehua Bio-engineering has received a medical device registration certificate from the Shanghai Municipal Drug Administration for its product "C-Reactive Protein (CRP) Test Kit" [2] - For the year 2024, the company's revenue composition is expected to be 100.0% from the biopharmaceutical sector [2]

格隆汇8月11日丨科华生物(002022.SZ)公布，近日，上海科华生物工程股份有限公司收到上海市药品监 督管理局颁发的医疗器械注册证(体外诊断试剂)。为C-反应蛋白(CRP)测定试剂盒(胶乳免疫比浊法)。 ...